A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary interventio

Phase 3

Completed

• Conditions: Acute coronairy syndroom; Heart diseases; 10028593

• Registration Number: NL-OMON30625
• Lead Sponsor: Quintiles

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Diagnostic coronary angiography demonstrating atherosclerosis (excluding ST segment-elevation) amenable to treatment by PCI with or without stent implantation

Exclusion Criteria

ST- Elevated MI patients who undergo PCI

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint:<br /><br>The primary efficacy endpoint is a composite incidence of all-cause mortality,<br /><br>MI, and IDR assessed<br /><br>48 hours after randomization.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints:<br /><br><br /><br>• Incidence of :<br /><br>- all-cause mortality and MI at 48 hours<br /><br>- all-cause mortality and MI at 30 days<br /><br>- all-cause mortality, MI and IDR at 30 days<br /><br>• Individual incidence of components of the composite (all-cause mortality, MI,<br /><br>and IDR)<br /><br>at 48 hours and 30 days<br /><br>• Incidence of stroke, distinguished by type, at 48 hours<br /><br>• Incidence of abrupt closure, threatened abrupt closure, need for urgent<br /><br>coronary artery bypass graft<br /><br>(CABG) surgery, or unsuccessful procedure during the index PCI<br /><br>• Incidence of all-cause mortality at 6 months (ascertained at the 1 year<br /><br>follow-up) and 1 year</p><br>